RT Journal Article
SR Electronic
T1 Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression
JF Life Science Alliance
JO Life Sci. Alliance
FD Life Science Alliance LLC
SP e202000955
DO 10.26508/lsa.202000955
VO 4
IS 2
A1 Rendeiro, André F
A1 Casano, Joseph
A1 Vorkas, Charles Kyriakos
A1 Singh, Harjot
A1 Morales, Ayana
A1 DeSimone, Robert A
A1 Ellsworth, Grant B
A1 Soave, Rosemary
A1 Kapadia, Shashi N
A1 Saito, Kohta
A1 Brown, Christopher D
A1 Hsu, JingMei
A1 Kyriakides, Christopher
A1 Chiu, Steven
A1 Cappelli, Luca Vincenzo
A1 Cacciapuoti, Maria Teresa
A1 Tam, Wayne
A1 Galluzzi, Lorenzo
A1 Simonson, Paul D
A1 Elemento, Olivier
A1 Salvatore, Mirella
A1 Inghirami, Giorgio
YR 2021
UL http://www.life-science-alliance.org/content/4/2/e202000955.abstract
AB With a rising incidence of COVID-19–associated morbidity and mortality worldwide, it is critical to elucidate the innate and adaptive immune responses that drive disease severity. We performed longitudinal immune profiling of peripheral blood mononuclear cells from 45 patients and healthy donors. We observed a dynamic immune landscape of innate and adaptive immune cells in disease progression and absolute changes of lymphocyte and myeloid cells in severe versus mild cases or healthy controls. Intubation and death were coupled with selected natural killer cell KIR receptor usage and IgM+ B cells and associated with profound CD4 and CD8 T-cell exhaustion. Pseudo-temporal reconstruction of the hierarchy of disease progression revealed dynamic time changes in the global population recapitulating individual patients and the development of an eight-marker classifier of disease severity. Estimating the effect of clinical progression on the immune response and early assessment of disease progression risks may allow implementation of tailored therapies.